Tag results:

Publication

CRKL but Not CRKII Contributes to Hemin-Induced Erythroid Differentiation of CML

[Journal of Cellular and Molecular Medicine] miR-429-CT10 regulation of kinase-like (CRKL) upregulation was negatively correlated with miR-429 downregulation in both chronic myeloid leemia (CML) patient and CR patient samples.

Myospreader Improves Gene Editing in Skeletal Muscle by Myonuclear Propagation

[Proceedings Of The National Academy Of Sciences Of The United States Of America] By screening nuclear localization signals and nuclear export signals, researchers identified “Myospreader,” a combination of short peptide sequences that promoted myonuclear propagation.

FLT3L Governs the Development of Partially Overlapping Hematopoietic Lineages in Humans and Mice

[Cell] The authors described three humans homozygous for a loss-of-function FMS-related tyrosine kinase 3 ligand (FLT3L) G variant with a history of various recurrent infections, including severe cutaneous warts.

Targeting Hyperactive Platelet-Derived Growth Factor Receptor-β Signaling in T Cell Acute Lymphoblastic Leukemia and Lymphoma

[Haematologica] Investigators reported a novel MYH9::PDGFRB fusion in a T-cell lymphoblastic lymphoma patient, and demonstrated that this fusion product was constitutively active and sufficient to drive oncogenic transformation in vitro and in vivo.

Molecular, Clinical, and Therapeutic Determinants of Outcome in NPM1 Mutated Aml

[Blood] Researchers analyzed a large group of patients with NPM1mutated AML enrolled in prospective trials to delineate the impact of baseline molecular and clinical features, post induction measurable residual disease status and treatment intensity on outcome.

Treatment of Chronic-Phase Chronic Myeloid Leukemia in Patients Randomized to Dasatinib or Imatinib after Suboptimal Responses to Three Months of Imatinib Therapy: Final 5-Year...

[Haematologica] DASCERN was a prospective, Phase IIb, randomized trial evaluating a switch to dasatinib in patients who have not achieved early molecular response after three months of treatment with first-line imatinib.

Popular